Current treatment of myelofibrosis.
Silver
Richard
R
Weill Medical College of Cornell University, NY, USA.
D001803:Blood Transfusion; D016026:Bone Marrow Transplantation; D002986:Clinical Trials as Topic; D003907:Dexamethasone / Q000008:administration & dosage / Q000627:therapeutic use; D019468:Disease Management; D004359:Drug Therapy, Combination; D004932:Esophageal and Gastric Varices / Q000209:etiology / Q000601:surgery; D051231:Farnesyltranstransferase / Q000037:antagonists & inhibitors; D006471:Gastrointestinal Hemorrhage / Q000209:etiology / Q000601:surgery; D016298:Hematopoietic Cell Growth Factors / Q000627:therapeutic use; D006801:Humans; D000077269:Lenalidomide; D011241:Prednisone / Q000008:administration & dosage / Q000627:therapeutic use; D055728:Primary Myelofibrosis / Q000150:complications / Q000188:drug therapy / Q000532:radiotherapy / Q000601:surgery / Q000628:therapy*; D011799:Quinazolines / Q000627:therapeutic use; D013154:Spleen / Q000528:radiation effects; D013156:Splenectomy; D013792:Thalidomide / Q000008:administration & dosage / Q000031:analogs & derivatives / Q000627:therapeutic use; D014184:Transplantation, Homologous
D016298:Hematopoietic Cell Growth Factors; D011799:Quinazolines; D013792:Thalidomide; D003907:Dexamethasone; D051231:Farnesyltranstransferase; D000077269:Lenalidomide; C021139:anagrelide; D011241:Prednisone